A study published this week in a major pharmaceutics journal reports oral bioavailability improvements for GLP-1-class peptides using a next-generation absorption-enhancer platform, potentially widening the path beyond the single approved oral formulation.
Oral semaglutide validated the concept commercially, but its low absolute bioavailability demands high API quantities. The new platform reports meaningfully higher absorption in primate models, which — if it translates — would change manufacturing economics for the whole class.
